Eton Pharmaceuticals Inc. (NASDAQ:ETON) went up by 1.42% from its latest closing price compared to the recent 1-year high of $10.30. The company’s stock price has collected 2.39% of gains in the last five trading sessions. Press Release reported on 05/28/21 that Eton Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Dehydrated Alcohol Injection
Is It Worth Investing in Eton Pharmaceuticals Inc. (NASDAQ :ETON) Right Now?
Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for Eton Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $12.50. ETON currently public float of 20.15M and currently shorts hold a 7.33% ratio of that float. Today, the average trading volume of ETON was 335.26K shares.
ETON’s Market Performance
ETON stocks went up by 2.39% for the week, with a monthly drop of -18.22% and a quarterly performance of -23.02%, while its annual performance rate touched 19.33%. The volatility ratio for the week stands at 7.03% while the volatility levels for the past 30 days are set at 6.99% for Eton Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -14.78% for ETON stocks with a simple moving average of -19.59% for the last 200 days.
Analysts’ Opinion of ETON
Many brokerage firms have already submitted their reports for ETON stocks, with H.C. Wainwright repeating the rating for ETON by listing it as a “Buy.” The predicted price for ETON in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on January 04th of the current year 2021.
B. Riley FBR, on the other hand, stated in their research note that they expect to see ETON reach a price target of $13.50. The rating they have provided for ETON stocks is “Buy” according to the report published on September 20th, 2019.
H.C. Wainwright gave a rating of “Buy” to ETON, setting the target price at $15 in the report published on June 10th of the previous year.
ETON Trading at -17.10% from the 50-Day Moving Average
After a stumble in the market that brought ETON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.67% of loss for the given period.
Volatility was left at 6.99%, however, over the last 30 days, the volatility rate increased by 7.03%, as shares sank -18.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.02% lower at present.
During the last 5 trading sessions, ETON rose by +2.39%, which changed the moving average for the period of 200-days by -2.87% in comparison to the 20-day moving average, which settled at $7.46. In addition, Eton Pharmaceuticals Inc. saw -21.03% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ETON starting from BRYNJELSEN SEAN, who purchase 5,000 shares at the price of $5.96 back on Jun 03. After this action, BRYNJELSEN SEAN now owns 1,030,000 shares of Eton Pharmaceuticals Inc., valued at $29,800 using the latest closing price.
Opaleye Management Inc., the 10% Owner of Eton Pharmaceuticals Inc., sale 126,000 shares at $8.49 during a trade that took place back on May 27, which means that Opaleye Management Inc. is holding 145,600 shares at $1,069,740 based on the most recent closing price.
Stock Fundamentals for ETON
Current profitability levels for the company are sitting at:
- -69515.38 for the present operating margin
- -2302.56 for the gross margin
The net margin for Eton Pharmaceuticals Inc. stands at -71717.95. The total capital return value is set at -142.51, while invested capital returns managed to touch -148.64. Equity return is now at value -121.00, with -66.20 for asset returns.
Based on Eton Pharmaceuticals Inc. (ETON), the company’s capital structure generated 45.60 points at debt to equity in total, while total debt to capital is 31.32. Total debt to assets is 27.14, with long-term debt to equity ratio resting at 43.81. Finally, the long-term debt to capital ratio is 30.09.
When we switch over and look at the enterprise to sales, we see a ratio of 4,016.88, with the company’s debt to enterprise value settled at 0.05. The receivables turnover for the company is 0.15 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.51.